What Pharma Can Learn From Military Intelligence
August 21, 2026
Former military intelligence officer Tony Page discusses what pharma can learn from early warning systems, decision cycles, and the discipline of intelligence
5 min read
False
Advertisement
Interviews
Musings from The Power List: Daniel Vitt
By Daniel Vitt
August 20, 2026
From multiple sclerosis to AI-driven discovery, Daniel Vitt reflects on the future of drug development
6 min read
The Mindset for Success in Biopharma's New Multipolar World
By Jessica Allerton, James Strachan
August 18, 2026
From collapsing legacy models to the rise of Chinese biotech, industry leaders are being forced to rethink how drugs are developed, funded, and brought to market
10 min read
Development & Clinical
Regulation & Standards
Business & Trends
Technology & Manufacturing
Sponsored
From Training Burden to Training Value
August 14, 2026
Why effective study training depends on relevance, timing, and oversight.
0 min read
Can Exosomes Unlock Nanomedicine’s Regenerative Medicine Potential?
August 12, 2026
NurExone CEO Lior Shaltiel discusses the company’s exosome-based approach to nerve regeneration, the manufacturing hurdles facing the field, and what it will take to bring nanotechnology therapeutics to patients
11 min read
Building Commercial Readiness in Advanced Therapies
August 10, 2026
Why early process development, analytical planning, and tech transfer can shape the future of cell and gene therapy manufacturing
5 min read
Moving Glycosylation Control Upstream
August 6, 2026
Samsung Biologics’ Sojeong Lee discusses why biologics developers are paying closer attention to glycosylation earlier in development.
7 min read
What Did ASCO 2026 Reveal About the Future of Oncology?
By James Strachan
August 6, 2026
Six drug development leaders discuss smarter immunotherapy combinations, the enduring potential of small molecules, emerging modalities, and how cancer treatment could evolve over the next two decades
8 min read
How China Is Rewriting the Rules Global Drug Development
By James Strachan
August 5, 2026
In part two of our conversation, Lingshi Tan explores how China’s integrated biopharma ecosystem is reshaping assumptions about speed, cost, innovation, and cross-border clinical development
14 min read
Single-Cell Analysis Reveals Hidden CAR T Manufacturing Risks
July 23, 2026
Mission Bio’s Mike Molnar explains how single-cell multiomics could improve vector copy number analysis, product characterization, and safety assessment in CAR T development
5 min read
